THE APEX TIMES
Lilly reports 52-week Phase 3b results combining Taltz and Zepbound in adults with psoriatic disease and obesity
New 52-week readouts from Lilly’s TOGETHER-PsO and TOGETHER-PsA trials add one-year data on the concomitant use of its ixekizumab and tirzepatide treatments in patients with psoriatic conditions and excess weight.
Eli Lilly and Co. said it has generated 52-week results from two open-label Phase 3b studies testing whether its Taltz and Zepbound can be used together in adults living with psoriatic disease and obesity. The company said the one-year data show improved and durable efficacy, as presented in an announcement carried by Yahoo Finance on Aug. 31.
Taltz is the brand name for ixekizumab, a biologic medicine used to treat several immune-mediated inflammatory conditions. Zepbound is tirzepatide, an injectable medicine originally developed for metabolic disease and also used in obesity management through its effects on appetite and blood-sugar pathways. Lilly’s trial concept pairs the anti-inflammatory mechanism of ixekizumab with the weight and metabolic effects of tirzepatide.
The studies, which Lilly described as TOGETHER-PsO and TOGETHER-PsA, evaluate the concomitant use of Taltz and Zepbound in adults with psoriatic disease and obesity. TOGETHER-PsO is aimed at psoriatic disease with obesity, while TOGETHER-PsA focuses on psoriatic arthritis. Both programs are described as novel open-label Phase 3b studies, meaning all participants receive the combination and results are observed over time rather than through blinded comparison arms.
Lilly characterized the 52-week findings as “improved and durable efficacy” at the one-year mark. The Yahoo Finance posting, as summarized in the provided material, did not include specific numerical outcomes, response rates, or comparative statistics in the text available here, so it is not possible to independently verify the magnitude of improvement from the information at hand.
The company’s interest in a paired regimen reflects a growing clinical and commercial focus on treating comorbid conditions together. Psoriatic disease affects both joints and skin in many patients, and excess weight is common in this population. By combining an immune-targeted therapy with an obesity and metabolic therapy, Lilly is probing whether controlling inflammation and body weight simultaneously could improve long-term disease control.
Sector context matters because tirzepatide-based medicines have expanded the obesity market and raised expectations for durable benefits beyond weight reduction, while psoriasis and psoriatic arthritis biologics remain competitive in inflammatory disease. If Lilly can demonstrate sustained improvements in patients with both conditions, it could support differentiated prescribing patterns that treat obesity as part of the overall disease burden rather than a separate target.
Still, there are gaps in what is disclosed in the summarized announcement. In the provided text, Lilly does not specify key endpoints, safety indicates, dosing schedules, subgroup results, or whether outcomes were assessed with standardized disease activity measures at 52 weeks. Without those details, it is unclear how the company’s results compare with what would be expected from each drug’s established monotherapy performance in similar populations.
For now, investors and clinicians will likely focus on what Lilly chooses to publish next, including the full 52-week dataset, safety details for the combination, and how the outcomes align with regulators’ expectations for Phase 3 evidence. A further readout could also clarify whether the company plans to advance the approach into later-stage studies and whether it will target specific patient groups within psoriatic disease and obesity.
Why It Matters
- If Lilly can substantiate sustained disease improvements in a comorbid population, it could strengthen the case for integrated treatment strategies in psoriatic disease.
- The results, if backed by full datasets, could shape how payers and clinicians think about combining biologics with obesity medicines in practice.
- The one-year readout adds timing evidence that may be important for durability claims, though the magnitude and clinical relevance depend on endpoints not included in the summarized text.
- The program also indicates Lilly’s intent to broaden tirzepatide’s positioning beyond obesity into adjacent inflammatory disease settings.
Key Facts
- Eli Lilly announced 52-week (one-year) results from two open-label Phase 3b trials evaluating concomitant use of Taltz (ixekizumab) and Zepbound (tirzepatide).
- The trials are TOGETHER-PsO and TOGETHER-PsA, aimed at adults with psoriatic disease and obesity, including psoriatic arthritis in TOGETHER-PsA.
- Lilly said the one-year results showed improved and durable efficacy for the combination.
- Taltz is ixekizumab, an immune-targeted biologic used for inflammatory conditions; Zepbound is tirzepatide, an injectable medicine used for obesity management via metabolic effects.
- The provided Yahoo Finance text summary does not include specific numeric efficacy outcomes or detailed safety disclosures.
Healthcare Related
Eli Lilly signs a $2.9 billion deal amid another run of acquisitions, as Zepbound trial updates bolster its obesity franchise
The drugmaker said it struck a $2.9 billion agreement as it continues an aggressive acquisition pace, while also reporting new late-stage data on Zepbound in combination with Taltz for adults with psoriasis-related conditions who are obese.
Eli Lilly agrees to buy Merida Biosciences in deal valued at up to $2.875 billion
The cash offer, announced Aug. 31, is designed to expand Eli Lilly’s immunology portfolio, according to a report.
Eli Lilly to buy Merida Biosciences in deal valued at up to $2.875 billion
The acquisition is aimed at expanding Eli Lilly’s antibody pipeline, including programs tied to Graves’ disease, thyroid eye disease and food allergy.
Report links Johnson & Johnson to a fast-growing palmoplantar pustulosis market, alongside AbbVie and other major drug makers
A new industry report says palmoplantar pustulosis is drawing more clinical attention and research into targeted biologic therapies, naming Johnson & Johnson among the companies profiled.
Johnson & Johnson’s stock portfolio spotlight: a “top” holding among 15 positions highlighted by Yahoo Finance
A recent market-leaning roundup says Johnson & Johnson holds stakes across 15 publicly traded stocks, with one investment standing out as the clearest leader by the post’s internal ranking.
Jim Cramer Highlights Moderna and Merck as Trial-Result Readthrough Lifts Shares in August
Moderna and Merck rose sharply in August after a widely watched market commentator pointed to encouraging trial results, according to a Yahoo Finance roundup.
Moderna’s 127% rally puts pressure on its cancer vaccine narrative, investors say
A sharp jump in Moderna shares has reignited attention on its pipeline, but one prominent market commentary argues that optimism around its MRNA cancer vaccine work may already be heavily reflected in the stock.
Eli Lilly faces a competitive test as Amylyx reports momentum in a GLP-1 candidate
A new market analysis suggests investors should watch whether Amylyx can translate early GLP-1 progress into credible commercial differentiation at a time when Eli Lilly remains the dominant U.S. GLP-1 franchise.
Eli Lilly’s Mounjaro steps further into heart-risk territory after FDA approval
The FDA has approved Mounjaro (tirzepatide) to reduce cardiovascular risk in adults with type 2 diabetes, giving Eli Lilly a broader label to pursue beyond glucose control.
UnitedHealth shares have led peers in the healthcare plans group, but analysts still face questions on outlook
A recent market note says UnitedHealth Group has outperformed healthcare-plan stocks over the past year, keeping Wall Street’s outlook on the company relatively constructive.
